Regulation of Thrombin Activity-Pharmacologic and Structural Aspects

Hematology/Oncology Clinics of North America

Volumn 21, Issue 1, 2007, Pages 33-50

  Tanaka, Kenichi A ^a   Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; CHONDROITIN SULFATE; DERMATAN SULFATE; DROTRECOGIN; FONDAPARINUX; HEPARIN; HEPARIN COFACTOR II; HIRUDIN; HIRULOG; INTIMATAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; MUTANT PROTEIN; PROTAMINE; RECOMBINANT ANTITHROMBIN III; RECOMBINANT THROMBOMODULIN; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANTICOAGULATION; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG PROTEIN BINDING; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; STROKE; THROMBOCYTOPENIA; THROMBOSIS;

ANTITHROMBINS; BLOOD COAGULATION; ENZYME ACTIVATION; HUMANS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 33846466747     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.11.008     Document Type: Review

References (94)

1. Bates S.M., and Weitz J.I. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol 144 8 (2005) 1017-1028
2. Butenas S., van't Veer C., and Mann K.G. "Normal" thrombin generation. Blood 94 7 (1999) 2169-2178
3. Di Cera E. Thrombin interactions. Chest 124 3 Suppl (2003) 11S-17S
4. Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 3 1 (2005) 54-67
5. Lane D.A., Philippou H., and Huntington J.A. Directing thrombin. Blood 106 8 (2005) 2605-2612
6. Murano G., Williams L., Miller-Andersson M., et al. Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 18 1-2 (1980) 259-262
7. Menache D., O'Malley J.P., Schorr J.B., et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75 1 (1990) 33-39
8. Rand M.D., Lock J.B., van't Veer C., et al. Blood clotting in minimally altered whole blood. Blood 88 9 (1996) 3432-3445
9. Brummel K.E., Paradis S.G., Butenas S., et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 100 1 (2002) 148-152
10. Huntington J.A., Read R.J., and Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 6806 (2000) 923-926
11. Langdown J., Johnson D.J.D., Baglin T.P., et al. Allosteric activation of antithrombin critically depends upon hinge region extension. J Biol Chem 279 45 (2004) 47288-47297
12. Ishiguro K., Kojima T., Kadomatsu K., et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 106 7 (2000) 873-878
13. Hirsh J., Piovella F., and Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 87 3B (1989) 34S-38S
14. Dietrich W., Spannagl M., Schramm W., et al. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 102 4 (1991) 505-514
15. Staples M.H., Dunton R.F., Karlson K.J., et al. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 57 5 (1994) 1211-1216
16. Tanaka K.A., Szlam F., Katori N., et al. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg 99 5 (2004) 1283-1289
17. Weitz J.I., Hudoba M., Massel D., et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86 2 (1990) 385-391
18. Berry C.N., Girardot C., Lecoffre C., et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72 3 (1994) 381-386
19. Salzman E.W., Rosenberg R.D., Smith M.H., et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 65 1 (1980) 64-73
20. Matsuo T., Nakao K., Yamada T., et al. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res 41 1 (1986) 33-41
21. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 3 (1998) 251-256
22. Stafford-Smith M., Lefrak E.A., Qazi A.G., et al. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 103 2 (2005) 229-240
23. Edmunds T., Van Patten S.M., Pollock J., et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 91 12 (1998) 4561-4571
24. Levy J.H., Despotis G.J., Szlam F., et al. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 96 5 (2002) 1095-1102
25. Avidan M.S., Levy J.H., van Aken H., et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 130 1 (2005) 107-113
26. O'Keeffe D., Olson S.T., Gasiunas N., et al. The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism. J Biol Chem 279 48 (2004) 50267-50273
27. Sheffield W.P., and Blajchman M.A. Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin. FEBS Lett 365 2-3 (1995) 189-192
28. Hoffman M., Loh K.L., Bond V.K., et al. Localization of heparin cofactor II in injured human skin: a potential role in wound healing. Exp Mol Pathol 75 2 (2003) 109-118
29. Halvorsen B., Aas U.K., Kulseth M.A., et al. Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins. Biochem J 331 3 (1998) 743-752
30. Zimmermann R., Sartipy P., Winkler R., et al. Endogenously produced glycosaminoglycans affecting the release of lipoprotein lipase from macrophages and the interaction with lipoproteins. Biochim Biophys Acta Mol Cell Biol Lipids 1484 2-3 (2000) 316-324
31. Abildgaard U. Binding of thrombin to antithrombin III. Scand J Clin Lab Invest 24 1 (1969) 23-27
32. Kurachi K., Fujikawa K., Schmer G., et al. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry 15 2 (1976) 373-377
33. Stead N., Kaplan A.P., and Rosenberg R.D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 251 21 (1976) 6481-6488
34. Kondo S., and Kisiel W. Regulation of factor VIIa activity in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromb Res 46 2 (1987) 325-335
35. Parker K.A., and Tollefsen D.M. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 260 6 (1985) 3501-3505
36. Church F.C., Noyes C.M., and Griffith M.J. Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci U S A 82 19 (1985) 6431-6434
37. Liaw P.C., Mather T., Oganesyan N., et al. Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor. Implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor. J Biol Chem 276 11 (2001) 8364-8370
38. Vicente C.P., He L., Pavao M.S., et al. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood 104 13 (2004) 3965-3970
39. Bertina R.M., van der Linden I.K., Engesser L., et al. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 57 2 (1987) 196-200
40. Kondo S., Tokunaga F., Kario K., et al. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). Blood 87 3 (1996) 1006-1012
41. He L., Vicente C.P., Westrick R.J., et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 109 2 (2002) 213-219
42. Takamori N., Azuma H., Kato M., et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 109 4 (2004) 481-486
43. Tanaka K.A., Szlam F., Vinten-Johansen J., et al. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thromb Haemost 94 4 (2005) 808-813
44. Buchanan M.R., and Brister S.J. Anticoagulant and antithrombin effects of Intimatan, a heparin cofactor II agonist. Thromb Res 99 6 (2000) 603-612
45. Andersson T.R., Sie P., Pelzer H., et al. Elevated levels of thrombin-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation. Thromb Res 66 5 (1992) 591-598
46. Taliani M.R., Agnelli G., Nenci G.G., et al. Dermatan sulphate in patients with heparin-induced thrombocytopenia. Br J Haematol 104 1 (1999) 87-89
47. Conway E.M., Van de Wouwer M., Pollefeyt S., et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196 5 (2002) 565-577
48. Weiler H., and Isermann B.H. Thrombomodulin. J Thromb Haemost 1 7 (2003) 1515-1524
49. Healy A.M., Rayburn H.B., Rosenberg R.D., et al. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A 92 3 (1995) 850-854
50. Isermann B., Hendrickson S.B., Zogg M., et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 108 4 (2001) 537-546
51. Esmon C.T. Inflammation and thrombosis. J Thromb Haemost 1 7 (2003) 1343-1348
52. Campbell W., Okada N., and Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 180 (2001) 162-167
53. Riewald M., Petrovan R.J., Donner A., et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296 5574 (2002) 1880-1882
54. Mosnier L.O., Gale A.J., Yegneswaran S., et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104 6 (2004) 1740-1744
55. Guo H., Liu D., Gelbard H., et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41 4 (2004) 563-572
56. Ludeman M.J., Kataoka H., Srinivasan Y., et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 280 13 (2005) 13122-13128
57. Riewald M., and Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 280 20 (2005) 19808-19814
58. Esmon C.T. The protein C pathway. Chest 124 3 Suppl (2003) 26S-32S
59. Salomaa V., Matei C., Aleksic N., et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353 9166 (1999) 1729-1734
60. Boldt J., Zickmann B., Schindler E., et al. Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations. J Thorac Cardiovasc Surg 107 5 (1994) 1215-1221
61. Liaw P.C.Y., Esmon C.T., Kahnamoui K., et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 104 13 (2004) 3958-3964
62. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 10 (2001) 699-709
63. Dhainaut J.F., Yan S.B., Margolis B.D., et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90 4 (2003) 642-653
64. Asakura H., Ontachi Y., Mizutani T., et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 67 3 (2001) 170-175
65. Wada H., Sakakura M., Kushiya F., et al. Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. Blood Coagul Fibrinolysis 16 1 (2005) 17-24
66. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 82 2 (1999) 718-721
67. Moll S., Lindley C., Pescatore S., et al. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2 10 (2004) 1745-1751
68. Kearon C., Comp P., Douketis J., et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 3 5 (2005) 962-968
69. Tanaka K.A., Fernandez J.A., Marzec U.M., et al. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. Br J Haematol 132 (2006) 197-203
70. Aritomi M., Watanabe N., Ohishi R., et al. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: thrombomodulin associates with free thrombin and is recycled to activate protein C. Thromb Haemost 70 3 (1993) 418-422
71. Warren B.L., Eid A., Singer P., et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286 15 (2001) 1869-1878
72. Okamoto S., Hijikata A., Kikumoto R., et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101 2 (1981) 440-446
73. Okamoto S. Strategies for creating new medicines. Kobe Research Project on Thrombosis and Hemostasis; 2003.
74. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl )sulfonyl]-L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 23 1 (1984) 85-90
75. Hofsteenge J., Stone S.R., Donella-Deana A., et al. The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin. Eur J Biochem 188 1 (1990) 55-59
76. Lefevre G., Duval M., Gauron S., et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 62 1 (1997) 50-59
77. Parry M.A., Maraganore J.M., and Stone S.R. Kinetic mechanism for the interaction of hirulog with thrombin. Biochemistry 33 49 (1994) 14807-14814
78. Kelly A.B., Maraganore J.M., Bourdon P., et al. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci U S A 89 13 (1992) 6040-6044
79. Witting J.I., Bourdon P., Brezniak D.V., et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 283 Pt 3 (1992) 737-743
80. Warkentin T.E., Greinacher A., Craven S., et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 94 (2005) 958-964
81. Noeske-Jungblut C., Haendler B., Donner P., et al. Triabin, a highly potent exosite inhibitor of thrombin. J Biol Chem 270 48 (1995) 28629-28634
82. Hanson S.R., Griffin J.H., Harker L.A., et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 92 4 (1993) 2003-2012
83. Cantwell A.M., and Di Cera E. Rational design of a potent anticoagulant thrombin. J Biol Chem 275 51 (2000) 39827-39830
84. Pineda A.O., Chen Z.W., Caccia S., et al. The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem 279 38 (2004) 39824-39828
85. Gruber A., Cantwell A.M., Di Cera E., et al. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem 277 31 (2002) 27581-27584
86. Macias W.L., Dhainaut J.F., Yan S.C., et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 72 4 (2002) 391-402
87. Shim K., Zhu H., Westfield L.A., et al. A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury. Blood 104 2 (2004) 415-419
88. Hosokawa K., Ohnishi T., Shima M., et al. Preparation of anhydrothrombin and characterization of its interaction with natural thrombin substrates. Biochem J 354 Pt 2 (2001) 309-313
89. Sakurai Y., Shima M., Giddings J., et al. A critical role for thrombin in platelet aggregation under high shear stress. Thromb Res 113 5 (2004) 311-318
90. Krem M.M., and Cera E.D. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 27 2 (2002) 67-74
91. Coughlin S.R., and Camerer E. Participation in inflammation. J Clin Invest 111 1 (2003) 25-27
92. Hemker H.C., Giesen P., Al Dieri R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 1 (2003) 4-15
93. Fernandez J.A., Xu X., Liu D., et al. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 30 3 (2003) 271-276
94. Malm K., Dahlback B., and Arnljots B. Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S. Thromb Haemost 90 2 (2003) 227-234